• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过脑脊液中苏氨酸231位点磷酸化的tau蛋白鉴别老年期重度抑郁症与阿尔茨海默病。

Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231.

作者信息

Buerger Katharina, Zinkowski Raymond, Teipel Stefan J, Arai Hiroyuki, DeBernardis John, Kerkman Daniel, McCulloch Cheryl, Padberg Frank, Faltraco Frank, Goernitz Alexander, Tapiola Tero, Rapoport Stanley I, Pirttilä Tuula, Möller Hans-Jürgen, Hampel Harald

机构信息

Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig-Maximilian University, Munich, Germany.

出版信息

Am J Psychiatry. 2003 Feb;160(2):376-9. doi: 10.1176/appi.ajp.160.2.376.

DOI:10.1176/appi.ajp.160.2.376
PMID:12562590
Abstract

OBJECTIVE

Differentiation of geriatric major depression from Alzheimer's disease is hampered by overlapping symptoms. Increased CSF concentrations of tau protein phosphorylated at threonine 231 (p-tau(231)) have been suggested as a biomarker for Alzheimer's disease. The authors asked whether p-tau(231) levels improve the differential diagnosis between geriatric major depression and Alzheimer's disease.

METHOD

Included were 34 depression subjects, 64 with probable Alzheimer's disease, 17 with possible Alzheimer's disease, and 21 healthy comparison subjects. P-tau(231) concentrations were measured with an enzyme-linked immunosorbent assay.

RESULTS

P-tau(231) levels were significantly higher in Alzheimer's disease than in geriatric major depression patients and healthy comparison subjects. For differentiation of probable Alzheimer's disease from major depression, p-tau(231) correctly allocated 87% of subjects. When possible mild Alzheimer's disease was compared to major depression, p-tau(231) correctly allocated 78% of subjects.

CONCLUSIONS

CSF p-tau(231) should be evaluated as a potential biological marker for differentiation of geriatric depression from Alzheimer's disease.

摘要

目的

老年重度抑郁症与阿尔茨海默病的症状重叠,这给两者的鉴别带来了困难。脑脊液中苏氨酸231位点磷酸化的tau蛋白(p-tau(231))浓度升高被认为是阿尔茨海默病的生物标志物。作者探讨了p-tau(231)水平是否有助于改善老年重度抑郁症与阿尔茨海默病之间的鉴别诊断。

方法

纳入34名抑郁症患者、64名可能患有阿尔茨海默病的患者、17名可能患有阿尔茨海默病的患者以及21名健康对照者。采用酶联免疫吸附测定法测量p-tau(231)浓度。

结果

阿尔茨海默病患者的p-tau(231)水平显著高于老年重度抑郁症患者和健康对照者。对于鉴别可能患有阿尔茨海默病与重度抑郁症,p-tau(231)能正确区分87%的受试者。当将可能患有轻度阿尔茨海默病的患者与重度抑郁症患者进行比较时,p-tau(231)能正确区分78%的受试者。

结论

脑脊液p-tau(231)应作为鉴别老年抑郁症与阿尔茨海默病的潜在生物学标志物进行评估。

相似文献

1
Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231.通过脑脊液中苏氨酸231位点磷酸化的tau蛋白鉴别老年期重度抑郁症与阿尔茨海默病。
Am J Psychiatry. 2003 Feb;160(2):376-9. doi: 10.1176/appi.ajp.160.2.376.
2
Increased tau protein differentiates mild cognitive impairment from geriatric depression and predicts conversion to dementia.tau蛋白增加可区分轻度认知障碍与老年抑郁症,并预测其向痴呆症的转化。
Neurosci Lett. 2007 Apr 6;416(1):39-42. doi: 10.1016/j.neulet.2007.01.070. Epub 2007 Feb 11.
3
Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease.克雅氏病中脑脊液总tau蛋白与苏氨酸231位点磷酸化tau蛋白之间的解离
Neurobiol Aging. 2006 Jan;27(1):10-5. doi: 10.1016/j.neurobiolaging.2004.12.003.
4
Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.泰国诗里拉吉医院对阿尔茨海默病(AD)及其他痴呆症患者的脑脊液(CSF)β-淀粉样蛋白(1-42)、磷酸化tau蛋白(ptau-181)和总tau蛋白进行评估。
J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.
5
Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease.早期和明显阿尔茨海默病患者中总tau蛋白及苏氨酸181位点磷酸化tau蛋白的水平。
Neurosci Lett. 2003 Mar 20;339(2):172-4. doi: 10.1016/s0304-3940(02)01481-7.
6
Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.特发性正常压力脑积水患者脑脊液中的tau蛋白、磷酸化tau181蛋白和β淀粉样蛋白1-42:与阿尔茨海默病的鉴别
Eur J Neurol. 2007 Feb;14(2):168-73. doi: 10.1111/j.1468-1331.2006.01593.x.
7
CSF phosphorylated tau--does it constitute an accurate biological test for Alzheimer's disease?脑脊液磷酸化tau蛋白——它能构成阿尔茨海默病的准确生物学检测方法吗?
Int J Geriatr Psychiatry. 2003 May;18(5):407-11. doi: 10.1002/gps.845.
8
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.磷酸化tau表位测量在阿尔茨海默病鉴别诊断中的应用:一项脑脊液对比研究
Arch Gen Psychiatry. 2004 Jan;61(1):95-102. doi: 10.1001/archpsyc.61.1.95.
9
Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.脑脊液标志物在阿尔茨海默病和血管性痴呆鉴别诊断中的作用
Coll Antropol. 2008 Jan;32 Suppl 1:31-6.
10
Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.认知健康的青年和老年人群中阿尔茨海默病的脑脊液标志物。
Alzheimers Dement. 2012 Nov;8(6):520-7. doi: 10.1016/j.jalz.2011.10.003. Epub 2012 Jun 6.

引用本文的文献

1
Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges.阿尔茨海默病:流行病学、风险因素、症状诊断、管理、护理、先进治疗方法及相关挑战的全面综述
Front Med (Lausanne). 2024 Dec 16;11:1474043. doi: 10.3389/fmed.2024.1474043. eCollection 2024.
2
Advances in cell membrane-based biomimetic nanodelivery systems for natural products.基于细胞膜的仿生纳米递药系统在天然产物中的研究进展。
Drug Deliv. 2024 Dec;31(1):2361169. doi: 10.1080/10717544.2024.2361169. Epub 2024 Jun 3.
3
Blood-based biomarkers for Alzheimer's disease.
用于阿尔茨海默病的基于血液的生物标志物。
EMBO Mol Med. 2022 Jan 11;14(1):e14408. doi: 10.15252/emmm.202114408. Epub 2021 Dec 3.
4
When Cognitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression.当老年人认知衰退与抑郁并存时:脑脊液生物标志物分析可区分阿尔茨海默病与老年期抑郁症。
Front Aging Neurosci. 2018 Feb 23;10:38. doi: 10.3389/fnagi.2018.00038. eCollection 2018.
5
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.阿尔茨海默病核心及新兴脑脊液生物标志物的最新进展
Croat Med J. 2014 Aug 28;55(4):347-65. doi: 10.3325/cmj.2014.55.347.
6
Current understanding of the neurobiology and longitudinal course of geriatric depression.当前对老年抑郁症神经生物学及病程的理解。
Curr Psychiatry Rep. 2014 Sep;16(9):463. doi: 10.1007/s11920-014-0463-y.
7
Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria.阿尔茨海默病 CSF 核心生物标志物的荟萃分析:新修订诊断标准后的最新进展。
Front Aging Neurosci. 2014 Mar 24;6:47. doi: 10.3389/fnagi.2014.00047. eCollection 2014.
8
Progress update: fluid and imaging biomarkers in Alzheimer's disease.进展更新:阿尔茨海默病中的流体和成像生物标志物
Biol Psychiatry. 2014 Apr 1;75(7):520-6. doi: 10.1016/j.biopsych.2013.07.031. Epub 2013 Sep 5.
9
Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.阿尔茨海默病健康老年人的脑脊液生物标志物。
Front Biosci (Landmark Ed). 2013 Jun 1;18(3):1150-73. doi: 10.2741/4170.
10
Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.阿尔茨海默病潜在的候选脑脊液生物标志物。
Biomark Med. 2012 Aug;6(4):455-76. doi: 10.2217/bmm.12.42.